

Meghan Shea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/125497/publications.pdf>

Version: 2024-02-01

30
papers

729
citations

759233

12
h-index

752698

20
g-index

30
all docs

30
docs citations

30
times ranked

1429
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of recurrent cervical cancer with peritoneal carcinomatosis with HIPEC. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100909.	0.6	1
2	A real-world study of patient characteristics and clinical outcomes in <i>EGFR</i> -mutated lung cancer treated with first-line osimertinib. <i>Journal of Clinical Oncology</i> , 2022, 40, e21033-e21033.	1.6	1
3	Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e379-e389.	2.6	13
4	Association of Performance Status With Survival in Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. <i>JAMA Network Open</i> , 2021, 4, e2037120.	5.9	73
5	Evaluating meaningful levels of financial toxicity in gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 801-806.	2.5	42
6	A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC). <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5609-TPS5609.	1.6	0
7	Implementing Electronic Patient-Reported Outcomes for Patients With New Oral Chemotherapy Prescriptions at an Academic Site and a Community Site. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 631-640.	2.1	5
8	Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. <i>Gynecologic Oncology</i> , 2020, 157, 357-366.	1.4	41
9	Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. <i>Gynecologic Oncology</i> , 2020, 157, 106-114.	1.4	29
10	Oral chemotherapy education: Hitting the mark?. <i>Journal of Clinical Oncology</i> , 2020, 38, 221-221.	1.6	0
11	Reply to R.J. Buckanovich et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2708-2709.	1.6	0
12	Financial toxicity in gynecologic oncology. <i>Gynecologic Oncology</i> , 2019, 154, 8-12.	1.4	78
13	PD-1 antibody pembrolizumab administered at non-standard frequency in non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, e20617-e20617.	1.6	0
14	Patients' perspectives and outcomes on an oral chemotherapy education and electronic monitoring program. <i>Journal of Clinical Oncology</i> , 2019, 37, e18007-e18007.	1.6	0
15	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. <i>Journal of the American Society of Cytopathology</i> , 2018, 7, 133-141.	0.5	56
16	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1037-1042.	1.1	83
17	Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. <i>Cancer Treatment and Research Communications</i> , 2018, 15, 17-20.	1.7	10
18	Maintenance PARP inhibitor therapy: is maintaining quality of life enough?. <i>Lancet Oncology</i> , The, 2018, 19, e504.	10.7	3

#	ARTICLE	IF	CITATIONS
19	Polymyositis as a presentation of advanced carcinoma of Mullerian origin: A case report and discussion. <i>Gynecologic Oncology Reports</i> , 2018, 25, 1-2.	0.6	2
20	Optimization of immune-related adverse event management in a thoracic oncology clinic.. <i>Journal of Clinical Oncology</i> , 2018, 36, 261-261.	1.6	0
21	Oral chemotherapy education sessions at an academic and community cancer center.. <i>Journal of Clinical Oncology</i> , 2018, 36, 254-254.	1.6	14
22	Electronic monitoring of patient-reported adherence and symptoms on oral chemotherapy at an academic and a community site.. <i>Journal of Clinical Oncology</i> , 2018, 36, 283-283.	1.6	9
23	Experience of financial toxicity among gynecologic oncology patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 90-90.	1.6	0
24	Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3â€“PD-L1 â‰¥50% Expression in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 878-883.	1.1	109
25	Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, e175-e177.	1.1	15
26	Learning from near misses: Addressing nursing chemotherapy verification fatigue.. <i>Journal of Clinical Oncology</i> , 2017, 35, 70-70.	1.6	0
27	Improving immune-related adverse event management in a thoracic clinic.. <i>Journal of Clinical Oncology</i> , 2017, 35, 74-74.	1.6	0
28	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 113-129.	2.6	125
29	Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutationâ€“Positive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, e81-e82.	1.1	20
30	Integrating nursing into oral chemotherapy education.. <i>Journal of Clinical Oncology</i> , 2016, 34, 81-81.	1.6	0